• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aspire Biopharma Holdings, Inc. - Common Stock (NQ:ASBP)

    1.050 -0.080 (-7.08%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Aspire Biopharma Holdings, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack
    Via ACCESS Newswire
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution
    Via ACCESS Newswire
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    News headline image
    Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
    Via ACCESS Newswire
    News headline image
    Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
    Via ACCESS Newswire
    Which stocks are moving on Thursday? ↗
    Via Chartmill
    Top stock movements in today's session. ↗
    Via Chartmill
    Top movers analysis in the middle of the day on 2026-01-14: top gainers and losers in today's session. ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Aspire Biopharma Announces Reverse Stock Split
    Via ACCESS Newswire
    Most active stocks in Thursday's session ↗
    Via Chartmill
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    Check out the stocks that are attracting the most attention and driving market activity. ↗
    Via Chartmill
    News headline image
    ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin –  Retail Expects Licensing Negotiations Soon ↗
    The FDA’s feedback supports a planned new drug application submission in the second half of 2026. 
    Via Stocktwits
    The market is filled with gapping stocks in Wednesday's session. ↗
    Via Chartmill
    Wednesday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
    Via ACCESS Newswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.